-
公开(公告)号：KR1020130130562A
公开(公告)日：2013-12-02
申请号：KR1020120054472
申请日：2012-05-22
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/4188 , A61K31/19 , A61P35/00
CPC classification number: A61K31/19 , A61K31/4188
Abstract: The present invention relates to a combined usage of valproic acid (VPA) for overcoming the resistance of cancer cells to temozolomide (TMZ), especially for O6-methylguanine-DNA methyltransferase (MGMT) expression reduction and temozolomide tolerance overcoming functions in neuroglioma cells.
Abstract translation: 本发明涉及克服癌细胞对替莫唑胺（TMZ）的抗性，特别是用于克服神经胶质瘤细胞功能的O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）表达降低和替莫唑胺耐受性的丙戊酸（VPA）的组合使用。
-
公开(公告)号：KR101594248B1
公开(公告)日：2016-02-15
申请号：KR1020140078978
申请日：2014-06-26
Applicant: 가톨릭대학교 산학협력단
Abstract: 본발명은 IL-8이처리된줄기세포의현저한혈관신생기능에관한것으로, 보다구체적으로는 IL-8이처리된중간엽줄기세포가 AKt 및 ERK를인산화시키는기작을통해 VEGF의분비를촉진시키고, 혈관신생을유도하여뇌졸중등의허혈성질환을효과적으로치료할수 있는용도에관한것이다.
-
公开(公告)号：KR1020150128043A
公开(公告)日：2015-11-18
申请号：KR1020140054764
申请日：2014-05-08
Applicant: 가톨릭대학교 산학협력단
IPC: A61K35/50 , A61K31/4188 , A61K35/44 , C12N5/0775 , C12N5/10 , A61P35/00
CPC classification number: A61K35/28 , A61K31/4188 , A61K2300/00
Abstract: 본발명은 TRAIL(Tumor necrosis factor-related apoptosis-inducing ligand)을분비하는줄기세포및 TMZ의조합에따른항암용도에관한것으로, 보다구체적으로는, 이들의조합에따른, DR5 발현의상향조절, ERK 활성화, 세포사멸억제단백질하향조절, 카스파아제활성화등의분자적메커니즘에의해신경교종세포를민감화(sensitizing)시킴으로써 TRAIL-매개된세포사멸능을강화시키는기능에관한것이다.
Abstract translation: 本发明涉及通过将分泌肿瘤坏死因子相关凋亡诱导配体（TRAIL）和TMZ的干细胞组合起来的抗癌用途，更具体地涉及通过使神经胶质瘤细胞增敏而增强TRAIL介导的细胞杀伤活性的功能 通过分子机制如上调DR5表达，ERK活化，凋亡抑制蛋白下调，半胱天冬酶活化。
-
公开(公告)号：KR101401891B1
公开(公告)日：2014-05-29
申请号：KR1020120054472
申请日：2012-05-22
Applicant: 가톨릭대학교 산학협력단
IPC: A61K31/4188 , A61K31/19 , A61P35/00
Abstract: 본 발명은 테모졸로미드(temozolomide, TMZ)에 저항성을 가지는 암세포에 대하여, 이를 극복할 수 있는 발프로산(valproic acid, VPA)의 병용 사용에 대한 것으로, 특히, 신경교종 세포에서 상기 발프로산의 MGMT(O6-methylguanine-DNA methyltransferase) 발현 감소 및 테모졸로미드 내성 극복기능에 관한 것이다.
-
公开(公告)号：KR1020130133318A
公开(公告)日：2013-12-09
申请号：KR1020120054470
申请日：2012-05-22
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K48/00 , A61K31/19 , A61K35/28 , A61K2300/00
Abstract: The present invention relates to a suicide-gene cancer therapy by combining valproic acid (VPA) with stem cells expressing suicide genes such as herpes simplex virus type I thymidine kinase (HSV-TK). Glioma cells and the suicide gene-expressing stem cells treated with the valproic acid are cultured in combination with each other, thereby up-regulating the gap junction and enhancing the bystander effect, leading to an increase in the anticancer effect.
Abstract translation: 本发明涉及通过将丙戊酸（VPA）与表达自杀基因（例如单纯疱疹病毒I型胸苷激酶（HSV-TK））的干细胞结合的自杀基因癌症治疗。 将由丙戊酸处理的胶质瘤细胞和表达自杀基因的干细胞相互组合培养，从而上调间隙连接并增强旁观者效应，导致抗癌作用增加。
-
Patent Agency Ranking
公开(公告)号：KR101305834B1
公开(公告)日：2013-09-06
申请号：KR1020110044953
申请日：2011-05-13
Applicant: 가톨릭대학교 산학협력단
Abstract: 본 발명은 방사선 조사 및 TRAIL 발현 간엽줄기세포 전달 치료의 결합을 이용해서 포유동물의 신경교종(glioma)을 치료하는 방법에 관한 것이다. 보다 구체적으로 본 발명은 TRAIL을 분비하는 간엽줄기세포(MSCs)를 포함하며, 방사선 요법 치료를 받는 신경교종 환자에게 투여되는 신경교종 치료용 조성물, 이의 제조방법 및 이를 이용한 치료방법에 관한 것이다. 본 발명에서 제공하는 TRAIL을 분비하는 형질전환된 사람 제대혈 유래-간엽줄기세포는 세포독성을 유발하지 않고 방사선 전처리 이후에 투여할 경우 상승적인 종양의 세포사멸 효과를 유도한다. 따라서 본 발명에 따른 TRAIL-발현 간엽줄기세포는 방사선 처리와 함께 사용되는 신경교종 치료제로서 활용될 수 있다.
-
公开(公告)号：KR1020120118619A
公开(公告)日：2012-10-29
申请号：KR1020110036097
申请日：2011-04-19
Applicant: 가톨릭대학교 산학협력단
CPC classification number: C12Q1/02 , C12N5/0619 , C12N2506/025 , C12N2506/1346 , G01N27/62 , G01N33/5008 , G01N33/60 , G01N33/68 , G01N2333/78
Abstract: PURPOSE: A material screening method for promoting differentiation to the nerve cell of stem cell is provided to rapidly and efficiently detect materials which help signal transmission so that the stem cells can be differentiated into nerve cells. CONSTITUTION: A material screening method for promoting differentiation to the nerve cell of stem cell comprises the following steps: processing candidate materials for neural cell differentiation promotion in the stem cell; measuring the phosphorylation of the beta - catenin in the cells; and assorting the candidate materials which multiply the phosphorylation activity of the beta - catenin by comparing with the stem cells which is not processed with the candidate materials. The stem cell is the mesenchyme stem cell. The mesenchyme stem cell is human umbilical cord originated cell. The processing of the candidate material is the overexpression of the candidate material by transformation.
Abstract translation: 目的：提供促进干细胞神经细胞分化的材料筛选方法，快速有效地检测有助于信号传导的物质，使干细胞分化成神经细胞。 构成：促进干细胞神经细胞分化的材料筛选方法包括以下步骤：处理干细胞中神经细胞分化促进的候选物质; 测量细胞中β-连环蛋白的磷酸化; 并通过与未用候选材料处理的干细胞进行比较，分类增加β-连环蛋白的磷酸化活性的候选物质。 干细胞是间充质干细胞。 间质干细胞是人脐带起源细胞。 候选材料的处理是通过转型对候选材料的过度表达。
-
公开(公告)号：KR100770669B1
公开(公告)日：2007-10-29
申请号：KR1020050117261
申请日：2005-12-03
Applicant: 가톨릭대학교 산학협력단
Abstract: 본 발명은 암(악성 뇌교종) 치료를 위한 골수 간엽줄기세포이 이용에 관한 것으로서, 더욱 구체적으로 골수 간엽줄기세포를 포함하는 악성 뇌교종 치료용 조성물 및 골수 간엽줄기세포의 면역효과세포로의 분화 및 활성화 방법에 관한 것이다.
본 발명에 따르면, 다양한 사이토카인으로 활성화된 MSCs는 뇌교종 세포주에 대한 강력한 세포독성을 나타내므로 본 발명의 조성물은 악성 뇌교종에 걸린 성인 및 아동에서 효과적인 입양(adoptive) 세포 전달의 소스로서 사용될 수 있을 것이다.-
19.发明公开
公开(公告)号：KR1020140147493A
公开(公告)日：2014-12-30
申请号：KR1020130070854
申请日：2013-06-20
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K35/28 , A61K35/15 , A61K38/215 , A61K47/50
Abstract: The present invention relates to a composition containing IFNβ-hBM mesenchymal stem cells (MSCs) to which IFN-β gene is introduced as an active ingredient for preventing or treating multiple sclerosis or encephalomyelitis; and to a method for producing the same. More specifically, the IFNβ-hBM-MSCs of the present invention have immunomodulatory functions of reducing Th1 cytokine in blood plasma and increasing Th2 cytokine in blood plasma; prevent demyelination of nerve cells; have a neuroprotective effect; and inhibit inflammatory infiltration or inhibit permeability of a blood brain barrier (BBB). Therefore, the composition can be used for preventing and treating multiple sclerosis and encephalomyelitis.
Abstract translation: 本发明涉及含IFN-βB基因的IFNβ-hBM间充质干细胞（MSC）的组合物，其作为预防或治疗多发性硬化症或脑脊髓炎的活性成分被引入。 及其制造方法。 更具体地，本发明的IFNβ-hBM-MSC具有减少血浆中Th1细胞因子和增加血浆中Th2细胞因子的免疫调节功能; 防止神经细胞脱髓鞘 具有神经保护作用; 并抑制炎性浸润或抑制血脑屏障（BBB）的通透性。 因此，该组合物可用于预防和治疗多发性硬化症和脑脊髓炎。
-
公开(公告)号：KR101455933B1
公开(公告)日：2014-10-31
申请号：KR1020130060458
申请日：2013-05-28
Applicant: 가톨릭대학교 산학협력단
CPC classification number: A61K31/65 , A61K35/28 , A61K2300/00
Abstract: The present invention relates to an administration of both human bone marrow mesenchymal stem cells (hBM-MSCs) and Minocycline. The Minocycline improves a clinical magnitude of multiple sclerosis, exhibits good effects for anti-inflammation, nerve protection, and long-term use, yet has toxicity in CNS. The hBM-MSCs have shown immunity adjusting functions and nerve protecting functions. Compared to when Minocycline or hBM-MSCs are individually used, a remarkable decrease is exhibited in a clinical score when both Minocycline and hBM-MSCs are administrated. Moreover, when both Minocycline and hBM-MSCs are administrated, immunity adjusting effects are reinforced, and inflammatory cytokines (IFN-γ, TNF-α) are controlled. In contrast, anti-inflammatory cytokines (IL-4, IL-10) are increased. Furthermore, when both Minocycline and hBM-MSCs are administrated, the number of dead cells is remarkably decreased through TUNEL coloring compared to individual administration. When both Minocycline and hBM-MSCs are administrated, provided is a protocol of a new technique for treating multiple sclerosis.
Abstract translation: 本发明涉及人骨髓间充质干细胞（hBM-MSC）和米诺环素的给药。 米诺环素改善了多发性硬化的临床严重程度，对抗炎，神经保护和长期使用具有良好的效果，但在CNS中具有毒性。 hBM-MSC显示出免疫调节功能和神经保护功能。 与米诺环素或hBM-MSCs单独使用相比，当给予米诺环素和hBM-MSCs时，在临床评分中显示出显着的降低。 此外，当给予米诺环素和hBM-MSC两者时，增强免疫调节作用，并且控制炎性细胞因子（IFN-γ，TNF-α）。 相比之下，抗炎细胞因子（IL-4，IL-10）增加。 此外，当给予米诺环素和hBM-MSC两者时，与单独给药相比，通过TUNEL染色显着降低死细胞数。 当给予米诺环素和hBM-MSC两者时，提供了治疗多发性硬化症的新技术的方案。
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.032 seconds)
